Thiogenesis Therapeutics has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare inherited mitochondrial disease with no approved treatments in the EU or US.
Thiogenesis Therapeutics presented updates on its clinical programs for Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) and Leigh Syndrome (LS) at the UMDF Webcast.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.